Illumina, Inc. (ILMN) Director Robert S. Epstein Sells 5,000 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Robert S. Epstein sold 5,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $310.44, for a total transaction of $1,552,200.00. Following the completion of the sale, the director now owns 8,256 shares in the company, valued at approximately $2,562,992.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Illumina stock opened at $325.52 on Friday. Illumina, Inc. has a twelve month low of $236.71 and a twelve month high of $372.61. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66. The stock has a market capitalization of $47.85 billion, a PE ratio of 56.91, a price-to-earnings-growth ratio of 2.17 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The firm had revenue of $846.00 million for the quarter, compared to the consensus estimate of $838.70 million. During the same period in the previous year, the firm posted $1.45 EPS. The business’s quarterly revenue was up 8.2% on a year-over-year basis. On average, equities analysts forecast that Illumina, Inc. will post 6.68 earnings per share for the current fiscal year.

Several analysts have commented on the stock. BidaskClub cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Canaccord Genuity restated a “buy” rating and issued a $350.00 target price (down from $360.00) on shares of Illumina in a report on Friday, April 26th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $355.00 target price on the stock in a report on Tuesday, April 2nd. OTR Global downgraded shares of Illumina to a “positive” rating in a report on Tuesday, April 2nd. Finally, Bank of America restated a “buy” rating and issued a $355.00 target price on shares of Illumina in a report on Wednesday, January 30th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $353.58.

A number of large investors have recently modified their holdings of ILMN. Massmutual Trust Co. FSB ADV grew its holdings in Illumina by 83.0% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 39 shares during the last quarter. Financial Advocates Investment Management grew its holdings in Illumina by 1,430.0% during the 4th quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 572 shares during the last quarter. Proficio Capital Partners LLC grew its holdings in Illumina by 61.7% during the 4th quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. C J Advisory Inc bought a new position in Illumina during the 1st quarter valued at about $29,000. Finally, Lake Point Wealth Management bought a new position in Illumina during the 4th quarter valued at about $30,000. Institutional investors own 90.56% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (ILMN) Director Robert S. Epstein Sells 5,000 Shares” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/05/illumina-inc-ilmn-director-robert-s-epstein-sells-5000-shares.html.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

See Also: The Structure of a Futures Contract

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.